Treatment for tumors comprising conjugated antibody A5B7 and a p

Details Treatment for tumors comprising conjugated antibody A5B7 and a p Treatment for tumors comprising conjugated antibody A5B7 and a p

1994-09-28

1997-05-27

Feisee, Lila

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

5303911, 5303888, 4241801, 4241931, 424 941, 435174, C12N 1500, C12P 2100, A61K 39395

Patent

active

056329903

ABSTRACT:
A treatment for tumors to which antibody A5B7 binds is disclosed. A5B7 is a monoclonal antibody which binds to carcinoembryonic antigen. The treatment comprises administering to a host in need of such treatment an effective amount of a system which comprises: a conjugate comprising antibody A5B7 or a humanized version of A5B7 linked to an enzyme selected from the group consisting of carboxypeptidase G2 (CPG2), nitroreductase, a human enzyme, a non-human enzyme rendered non-immunogenic in man and a humanized catalytic antibody; and a prodrug convertible under the influence of the conjugate into a cytotoxic drug.

REFERENCES:
patent: 4185111 (1980-01-01), Ducep et al.
patent: 4564675 (1986-01-01), Kurabayashi et al.
patent: 4675187 (1987-06-01), Konishi et al.
patent: 4762707 (1988-08-01), Jansen et al.
patent: 4975278 (1990-12-01), Senter et al.
Radford Infection and Immunity vol. 56 No. 4, Apr. 1988 921-925.
Searle et al. Br. J. Cancer 1986 (53) 377-384.
Oshaud et al. Immunology Today vol. 11 No. 6, 1990 (193).
Waldman Science vol. 252 1991 p. 1657.
Harris TibTech 1993 vol. 11 p. 42.
Reichman Nature vol. 332 1988 p. 323.
Hird et al Genes and Cancer Ed. By Carney and Sikore 1990.
Harwood et al., "Mapping epitope characteristics on carcinoembryonic antigen", Br. J. Cancer 54: 75-82 (1986).
Pedley et al., "Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft", Eur. J. Nucl. Med 13: 197-202 (1987).
Blakey et al., "Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs", Br. J. Cancer 72: 1083-1088 (1995).
Sharma et al., "Pharmacokinetics of monoclonal anti-CEA antibody-enzyme (A5B7-F(ab').sub.2 -CPG2) conjugate in Adept." Antibody Immunoconjugates and Radiopharmaceuticals 62:16'(1995).
Blakey et al., "Comparison of the Cellular Internalization of Antibodies Used Either as Immunotoxins or in Adept", Cell Biophysics 24/25: 175-183 (1994).
Bagshawe et al., "Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial", Tumor Targeting 1: 17-29 (1995).
"Monoclonal and Polyclonal Antibodies and Kits", p. 68 of a catalogue of Dako Ltd. (1991).
Nap et al., "Specificity and Affinity of Monoclonal Antibodies against Carcinoembryonic Antigen", Cancer Research 52: 2329-2339 (1992).
Editors: Carl A.K. Borrebaeck and James W. Larrick, "Therapeutic Monoclonal Anitbodies", pp. 17-141 (1990).
I. Hellstrom et al., "Monoclonal Mouse Antibodies Raised against Human Lung Carcinoma", Cancer Research, 46, pp. 3917-3923 (Aug. 1986).
G. W. Philpott et al., "Affinity Cytotoxicity of Tumor Cells with Antibody-Glucose Oxidase Conjugates, Peroxidase, and Arsphenamine", Cancer Research, 34, pp. 2159-2164 (Sep. 1974).
I. Hellstrom et al., "Monoclonal Antibodies to Two Determinants of Melanoma-Antigen p97 Act Synergistically in Complement-Dependent Cytotoxicity", The Journal of Immunology, 127(1), pp. 157-160 (Jul. 1981).
V. J. Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery", Directed Drug Delivery, pp. 247-267 (1985).
T. Nishiyama et al., "Antineoplastic Effects in Rats of 5-Fluorocytosine in Combination with Cytosine Deaminase Capsules", Cancer Research, 45, pp. 1753-1761 (Apr. 1985).
D. E. V. Wilman, "Prodrugs in Cancer Chemotherapy", Biochemical Society Transactions, 14, pp. 375-382, (615th Meeting, Belfast 1986).
P. J. O'Dwyer et al., The New England Journal of Medicine, 312, pp. 692-700 (Mar. 14th, 1985).
A. P. Albino et al., "Heterogeneity of Surface Antigen and Glycoprotein Expression of Cell Lines Derived from Different Melanoma Metastases of the Same Patient", J. Exp. Med., 154, pp. 1764-1778 (Dec. 1981).
R. Arnon et al., "In Vitro and In Vivo Efficacy of Conjugates of Daunomycin with Anti-Tumor Antibodies", Immunological Rev., 62, pp. 5-27, (1982).
K. D. Bagshawe, "Antibody Directed Enzymes Revive Anti-Cancer Prodrugs Concept", Br. J. Cancer, 56, pp. 531-532 (Nov. 1987).
K. D. Bagshawe, "A Novel Approach to Prodrug Activation Using a Monoclonal Antibody Conjugated to Carboxypeptidase G2", from the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, Abstract #43, p. 70 (San Diego, Feb. 4-6, 1988).
R. W. Baldwin et al., "Design and Therapeutic Evaluation of Monoclonal Antibody 791T/36-Methotrexate Conjugates" Monoclonal Antibodies and Cancer Therapy, pp. 215-231 (Alan R. Liss, Inc. 1985).
R. W. Baldwin et al., "Monoclonal Antibodies in Cancer Treatment", Lancet, pp. 603-605 (Mar. 15, 1986).
R. W. Baldwin et al. "Monoclonal Antibody Drug Conjugagates for Cancer Therapy", Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment, Jack A. Roth (ed)., pp. 215-257 (Futura Publishing Co., 1986).
J. P. Brown et al., "Structural Characterization of Human Melanoma-Associated Antigen p97 with Monoclonal Antibodies", J. Immunology, 127(2), pp. 539-546, (Aug. 1981).
E. A. Clark et al., "Role of the Bp35 Cell Surface Polypeptide in Human B-Cell Activation", Proc.Natl.Acad.Sci., 82, pp. 1766-1770 (Mar. 1985).
S. T. Crooke et al. (eds.) Anthracyclines: Current Status and New Developments, Academic Press, cover pages and table of contents, (New York, 1980).
R. A. DeWeger et al., "Eradication of Murine Lymphoma and Melanoma Cells by Chlorambucil-Antibody Complexes", Immunological Rev., 62, pp. 29-45 (1982).
M. J. Embleton et al., "Antibody Targeting of Anti-Cancer Agents", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin and V. S. Byers (eds.), pp. 321-322 (Academic Press, 1985).
M. J. Embleton, "Targeting of Anti-Cancer Therapeutic Agents by Monoclonal Antibodies", Biochemical Society Transactions, 14, pp. 393-395 (615th Meeting, Belfast 1986).
N. Endo et al., "In Vitro Cytotoxicity of a Human Serum Albumin-Medicated Conjugate of Methotrexate with Anti-MM46 Monclonal Antibody", Cancer Research, 47, pp. 1076-1080 (Feb. 15th, 1987).
P. J. Fraker et al., "Protein and Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril", Biochem. Biophysical Comm., 80(4), pp. 849-857 (Feb.1978).
I. Hellstrom et al., "Antitumor Effects of L6, an IgG2a Antibody that Reacts with Most Human Carcinomas", Pro.Natl.Acad.Sci.U.S.A., 83, pp. 7059-7063 (Sep. 1986).
I. Hellstrom et al., "Antibodies for Drug Delivery", Controlled Drug Delivery (2nd ed.), Robinson and Lee (eds.), pp. 638-642 (1987).
P. L. Ipata et al., "Baker's Yeast Cytosine Deaminase. Some Enzymic Properties and Allosteric Inhibition by Nucleosides and Nucleotides", Biochemistry, 10(23) pp. 4270-4276 (1971).
T. Katsuragi et al., "Affinity Chromatography of Cytosine Deaminase from Escherichia coli with Immobilized Pyrimidine Compounds", Agric. Biol. Chem., 50(7), pp. 1713-1719 (1986).
J. M. Lambert et al., "Purified Immunotoxins That Are Reactive with Human Lymphoid Cells", J. Biol. Chemistry 260(22), pp. 12035-12041 (1985).
J. P. Mach et al., "Improvement of Colon Carcinoma Imaging: From Polyclonal Anti-CEA Antibodies and Static Photoscanning to Monoclonal Fab Fragments and ECT", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al (eds), pp. 53-64, Academic Press (1985).
R. B. McComb et al. (eds)., Alkaline Phosphatase, Plenum Press, Chapters 4, 5, 6 and 11 (New York 1979).
R. G. Melton et al., "In Vivo Localization of Carboxypeptidase G2:Antibody Conjugates in Human Colon Carcinoma Xenografts", from the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer Abstract #83, p. 110 (San Diego, Feb. 4-6, 1988).
S. Monfardini et al. (eds), Manual of Cancer Chemotherapy, Third Edition, UICC Technical Report Series, 56, Table of Contents, pp. 1-230 (Geneva 1981).
F. L. Moolten et al., "Antibodies Conjugated to Potent Cytotoxins as Specific Antitumor Agents", Immunological Rev., 62, pp. 47-73 (1982).
K. Ohkawa et al., "Selective in Vitro and In Vivo Growth Inhibition Against Human Yolk Sac Tumor Cell Lines by Purified Antibody Against Human .alpha.-Fetoprotein Conjugated with Mitomycin C via Human Serum Albumin", Cancer Immunol. Immunother, 23, pp. 81-86 (1986).
C. W. Parker et al., "Enzymat

Affiliated with

Also associated with

Rating

Treatment for tumors comprising conjugated antibody A5B7 and a p does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment for tumors comprising conjugated antibody A5B7 and a p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for tumors comprising conjugated antibody A5B7 and a p will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2327179